ArticleScientific reports2025
Keratin 80 as a diagnostic biomarker with limited prognostic value in non-small cell lung cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- KRT80 promotes colon adenocarcinoma progression via stat3 pathway activation and immune microenvironment remodeling.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
To investigate the expression of KRT80 in non-small cell lung cancer (NSCLC) patients and its relationship with clinicopathological factors, prognosis, as well as the differences in KRT80 expression between Xuanwei area and Non-xuanwei area, lung adenocarcinoma and lung squamous cell carcinoma. Based on 178 clinical cases, immunohistochemical methods combined with public databases were used to examine the expression of KRT80 in NSCLC patients and analyze its correlation with various clinicopathological factors and prognosis. The study confirmed the up-regulation of KRT80 expression in NSCLC cancer tissues. Significant regional specific and histological subtype differences in KRT80 expression were revealed. Although the expression level of KRT80 has no direct significant correlation with the prognosis of NSCLC patients, it has a good ability to distinguish cancerous tissue from paracancer tissue. KRT80 can be used as a diagnostic biomarker for NSCLC patients, but its specific mechanism and clinical application value still need to be further explored.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.